Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618268 | 0.80 | KDM4E (0.43) | KDM4EMAPTNSD2ALDH1A1BACE1 | |
| SCHEMBL22130148 | 0.74 | KDM4E (0.59) | KDM4EMAPTNSD2ALDH1A1BACE1 | |
| SCHEMBL28028402 | 0.74 | BRAF (0.47) | KDM4EMAPTNSD2ALDH1A1BACE1 | |
| SCHEMBL29303290 | 0.72 | KDM4E (0.42) | KDM4EMAPTNSD2ALDH1A1BACE1 | |
| SCHEMBL6618263 | 0.72 | KDM4E (0.40) | KDM4EMAPTNSD2ALDH1A1BACE1 | |
| SCHEMBL27914445 | 0.71 | BACE1 (0.41) | KDM4EMAPTNSD2ALDH1A1BACE1 | |
| SCHEMBL22926317 | 0.71 | KDM4E (0.41) | KDM4EMAPTNSD2ALDH1A1BACE1 | |
| SCHEMBL2752348 | 0.68 | MAPT (0.45) | MAPTALDH1A1 | |
| SCHEMBL16595983 | 0.68 | MAOA (0.46) | KDM4EBACE1CHRM1KDM1AMAOA | |
| SCHEMBL422738 | 0.68 | KDM4E (0.50) | KDM4EMAPTNSD2ALDH1A1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626103-B2 | Inhibitor of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626103-B2 | Inhibitor of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM4E 15/4885MAPT 2977/4885NSD2 150/4885 |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM4E 15/4885MAPT 2977/4885NSD2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.